Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy)


1 Department of Anatomy, Islamic Azad University Tehran Medical Branch, Tehran, Iran

2 Department of Anatomy, Tehran University of Medical Sciences, Tehran, Iran

3 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran


Objective(s): 3,4-Methylenedioxymethamphetamine (MDMA) is one of the most popular drugs of abuse in the world with hallucinogenic properties that has been shown to induce apoptosis in  liver cells. The present study aimed to investigate the effects of pentoxifylline (PTX) on liver damage induced by acute administration of MDMA in Wistar rat.
Materials and Methods: Animals were administered with saline or MDMA (7.5 mg/kg, IP) 3 times with 2 hr intervals. PTX (200 mg kg, IP), was administered simultaneously with last injection of MDMA in experimental group.
Results: The concomitant administration of pentoxifylline and MDMA decreased liver injury including apoptosis, fibrosis and hepatocytes damages.
Conclusion: Our results showed for the first time that PTX treatment diminishes the extent of apoptosis and fibrosis caused by MDMA in rat liver.


1. Ricaurte GA, Bryan G, Strauss L, Seiden LS, Schuster CR. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229:986-988.
2. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16:3041-3053.
3. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352:1751–1752.
4. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159:2221–2224.
5. Kuypers KP, Samyn N, Ramaekers JG. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology 2006; 187:467–475.
6. Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage. J Clin Gastroenterol 1995; 20:244-247.
7. Cerretani D, Bello S, Cantatore S, Fiaschi AI, Montefrancesco G, Neri M, Pomara C. Acute administration of 3,4-methylenedioxymethamphetamine (MDMA) induces oxidative stress, lipoperoxidation and TNFα-mediated apoptosis in rat liver. Pharmacol Res 2011; 64:517-527.
8. Turillazzi E, Riezzo I, Neri M, Bello S, Fineschi V. MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings. Curr Pharm Biotechnol 2010; 11:500-509.
9. Carvalho M, Pontes H, Remião F, Bastos ML, Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol 2010; 11:476-495.
10. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Carvalho F, et al. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004; 200:193–203.
11. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000; 13:135–160.
12. Montiel-Duarte C, Ansorena E, Lopez-Zabalza MJ, Cenarruzabeitia E, Iraburu MJ,Cenarruzabeitia E,et -al. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxy methamphetamine ("Ecstasy") on hepatic stellate cells. Biochem Pharmacol 2004; 67:1025–1033.
1. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 1992; 13:391–405.
14. Milhazes N, Cunha-Oliveira T, Martins P, Garrido J, Oliveira C, Rego AC, Borges F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship. Chem Res Toxicol 2006; 19:1294–1304.
15. Fisher AA, Labenski MT, Malladi S, Gokhale V, Bowen ME, Milleron RS, et al. Quinone electrophiles selectively adduct "electrophile binding motifs" within cytochrome c. Biochemistry 2007; 46:11090–11100.
16. Moon KH, Hood BL, Kim BJ, Hardwick JP, Conrads TP, Veenstra TD, et al.  Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology 2006; 44:1218–1230.
17. Moon KH, Abdelmegeed MA, Song BJ. Inactivation of cytosolic aldehyde dehydrogenase via                       S-nitro sylation in ethanol-exposed rat liver. FEBS Lett 2007; 581:3967–3972.
18. Seiffge D. Pentoxifylline: its influence on interaction of blood cells with the vessel wall. Atherosclerosis 1997; 131: 27–28.
19. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997; 29:181–196.
20. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G497-502.
21. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637–1648.
22. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48:465–470.
23. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 7: 15:1613-1619.
24.Wu J, Liu J, Waalkes MP, Cheng ML, Li L, Li CX, et al. High dietary fat exacerbates arsenic-induced liver fibrosis in mice. Exp Biol Med (Maywood) 2008; 233:377-384.
25. Moragas AH, Allende M. Sans: Characteristics of perisinusoidal collagenization in liver cirrhosis: Computer-assisted quantitative analysis. Anal Quant Cytol Histol 1998; 20:169–177.
26. Upreti VV, Moon KH, Yu LR, Lee IJ, Eddington ND, Ye X, Veenstra TD, Song BJ. Increased oxidative-modifications of cytosolic proteins in 3, 4 methylenedioxymethamphetamine (MDMA, ecstasy)-exposed rat liver. Proteomics 2011; 11:202-211

27. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis  2005 ;10:927-939.

28. Brichese L, Cazettes G, Valette A. JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2. Cell Cycle 2004; 3:1312–1319.
29. De Chiara G, Marcocci ME, Torcia M, Lucibello M, Rosini P, Bonini P, et al. Bcl-2 Phosphorylation by p38 MAPK:identification of target sites and biologic consequences. J Biol Chem 2006; 281:21353–21361.
30. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996; 38:454-458.
31. Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C. Pentoxifylline، a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol 2009; 15: 3194-3195.
32. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613-1619.
33. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78:1205-1211.
34. Stockschläder M, Kalhs P, Peters S, Zeller W, Krüger W, Kabisch H, Lechner K, Zander A. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:357-362.
35. van Miert AS, van Duin CT, Wensing T. Effects of pentoxifylline and polymyxin B on the acute-phase-response to Escherichia coli endotoxin in dwarf goats. J Vet Pharmacol Ther 1997; 20:61-68.
36. Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H, Lilly CM, O'Hanley PT, Raffin TA. The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 1989; 140:974-980.
37. Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev 2010; 90:1165-1194.
38. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour4 necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004; 19:1106-1115.
39. McHutchison JG, Runyon BA, Draguesku JO, Cominelli F. Person JL, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14:96A
40. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637-1648.
41. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010 21; 16:4905-4912.
42. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002 ; 50:241-247.
43. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10:49.